US FDA approves evinacumab as an adjunct for the treatment of homozygous familial hypercholesterolaemia in patients ≥12 years

Evinacumab is a monoclonal antibody against angiopoietin-like protein 3. The approval was based on results from the Phase III ELIPSE trial, in which it lowered LDL cholesterol at week 24 (relative reduction of 47.1% vs increase of 1.9% with placebo; p<0.001).

Source:

Biospace Inc.